翰森制药(03692.HK) 公布,集团与广州麓鹏制药合作的1类小分子布鲁顿酪氨酸激酶抑制剂HS-10561胶囊获中国国家药品监督管理局签发的药物临床试验批准通知书,拟开展用于慢性自发性荨麻疹的临床试验。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-25 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.